Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Life Without Plavix: Sanofi Highlights Next Generation Drugs

Executive Summary

Sanofi will lose exclusivity for Plavix, Avapro and Eloxatin in 2012, driving what it expects will be a 12% to 15% EPS decline, but management is counting on a new wave of drugs – and the addition of Genzyme – to return to growth.

You may also be interested in...



Deals Of The Week: Celgene/Acetylon, Cytomedix/Aldagen, Vernalis/Tris Pharma

CEOs from Sanofi and GlaxoSmithKline hold forth on how previous years’ preparations have led up to this moment, a post-patent-cliff future for big pharma.

Amylin’s Bydureon Approval: How Does It Sit With Novo Nordisk?

Sponsor of the leading GLP-1 agonist, Victoza, sees the launch of the long-acting competitor from Amylin as having a class-wide impact, drawing more patients to GLP-1s – and it thinks that it can stave off the once-weekly contender.

More Insulin Innovation To Come, Says Novo CEO Sorensen

Market-leader Novo is confident it can continue to innovate in insulin – and command premium prices

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS054185

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel